|
Market Closed -
Nasdaq
21:00:00 09/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 27.68 USD | +0.36% |
|
-4.32% | +3.63% |
| 08-25 | Deutsche Bank Adjusts ACADIA Pharmaceuticals PT to $38 From $37, Maintains Buy Rating | MT |
| 08-25 | EU Approves Acadia Pharmaceuticals' Rett Syndrome Drug Daybu | MT |
| Market Cap | 4.77B 4.1B 3.86B 3.52B 6.59B 454B 6.61B 45.8B 17.7B 231B 17.91B 17.52B 732B | P/E 2026 * |
45.7x | P/E 2027 * | 32.2x |
|---|---|---|---|---|---|
| Enterprise Value | 3.76B 3.24B 3.05B 2.78B 5.19B 358B 5.22B 36.11B 13.96B 182B 14.12B 13.81B 578B | EV / Sales 2026 * |
2.95x | EV / Sales 2027 * | 2.46x |
| Free-Float |
99.67% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| ACAD | Delayed | |
CBOE
| ACAD | Real-time | |
|
Mexican S.E.
| ACAD * | End-of-day quote | |
|
Tradegate
| DR6 | Real-time | |
|
Deutsche Boerse AG
| DR6 | Delayed | |
|
Börse Stuttgart
| DR6 | Delayed | |
|
Boerse Muenchen
| DR6 | Real-time |
Last Transcript : ACADIA Pharmaceuticals Inc.
| 1 day | +0.36% | ||
| 1 week | -4.32% | ||
| Current month | -4.25% | ||
| 1 month | -5.24% | ||
| 3 months | +26.74% | ||
| 6 months | +22.59% | ||
| Current year | +3.63% |
| 1 week | 27.1 |  | 28.19 |
| 1 month | 27.1 | | 30.96 |
| Current year | 19.89 | | 30.96 |
| 1 year | 19.69 | | 30.96 |
| 3 years | 13.4 | | 32.59 |
| 5 years | 12.24 | | 33.99 |
| 10 years | 12.24 | | 58.72 |
| Manager | Title | Age | Since |
|---|---|---|---|
Catherine Adams
CEO | Chief Executive Officer | 55 | 19/09/2024 |
Mark Schneyer
DFI | Director of Finance/CFO | 52 | 09/09/2021 |
Scott Cenci
CTO | Chief Tech/Sci/R&D Officer | - | 03/08/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Laura Brege
BRD | Director/Board Member | 68 | 30/04/2008 |
Stephen Biggar
CHM | Chairman | 55 | 09/06/2016 |
Edmund Harrigan
BRD | Director/Board Member | 73 | 24/11/2015 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 06/08/26 | Exercice | Chief Financial Officer | 42,876 | 0.0250% | ||
| 30/07/26 | Sell | Chief Technology Officer | -16,558 | 0.0097% | ||
| 29/05/26 | Exercice | Director | 41,529 | 0.0243% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.36% | -4.32% | +11.43% | +4.65% | 4.77B | |
| +0.87% | -6.98% | -2.73% | +11.12% | 46.38B | |
| +0.17% | -0.74% | +407.28% | +546.58% | 44.51B | |
| -0.86% | -2.60% | +35.51% | +20.35% | 42.3B | |
| -0.14% | -2.98% | -0.04% | +82.21% | 39.91B | |
| 0.00% | -1.72% | +13.42% | +42.33% | 32.79B | |
| -3.44% | -2.43% | - | - | 17.13B | |
| -0.78% | -1.13% | +20.74% | +116.26% | 16.36B | |
| -0.11% | -3.76% | +12.33% | +30.49% | 14.31B | |
| -0.86% | -4.60% | +76.86% | +39.36% | 13.29B | |
| Average | -0.51% | -3.03% | +63.87% | +99.26% | 27.18B | |
| Weighted average by Cap. | -0.31% | -3.06% | +84.58% | +130.62% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.27B 1.1B 1.03B 940M 1.76B 121B 1.76B 12.22B 4.72B 61.69B 4.78B 4.67B 195B | 1.43B 1.23B 1.16B 1.06B 1.98B 136B 1.99B 13.76B 5.32B 69.48B 5.38B 5.26B 220B |
| Net income | 106M 90.84M 85.54M 77.94M 146M 10.05B 146M 1.01B 392M 5.12B 396M 388M 16.21B | 156M 135M 127M 115M 216M 14.88B 217M 1.5B 580M 7.58B 587M 575M 24.02B |
| Net Debt | -1.01B -868M -817M -745M -1.39B -96.01B -1.4B -9.69B -3.74B -48.91B -3.79B -3.71B -155B | -1.24B -1.06B -1B -913M -1.71B -118B -1.72B -11.88B -4.59B -59.97B -4.65B -4.54B -190B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 09/09/26 | US$27.68 | +0.36% | 1,293,919 |
| 08/09/26 | US$27.58 | -1.57% | 1,457,760 |
| 04/09/26 | US$28.02 | +0.57% | 1,682,950 |
| 03/09/26 | US$27.86 | -3.70% | 1,849,411 |
| 02/09/26 | US$28.93 | +0.14% | 1,555,986 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ACAD Stock
Select your edition
All financial news and data tailored to specific country editions
